ADVANCED BREAST CANCER

This study is testing whether taking pyrotinib continuously or with planned breaks works better for people with advanced HER2-positive breast cancer. Researchers want to see which approach controls the cancer more effectively while potentially reducing side effects. The trial wil…

This study is testing whether different antibody-drug conjugate (ADC) medications can help control advanced breast cancer in patients whose cancer has progressed despite previous ADC treatment. The trial will enroll 160 adults with metastatic breast cancer who have already receiv…

This study is testing how well the drug dalpiciclib works to control advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers will follow 103 patients in real-world settings to see how long the drug keeps the cancer from worsening and monitor any si…

This early-stage study is testing a new oral medication called PF-08032562, both alone and in combination with other cancer drugs, for people with advanced or metastatic breast or colorectal cancer. The main goals are to find a safe dose and see how the body processes the drug. R…

This trial is testing whether a new oral medication called OP-1250 works better than current standard hormone therapies for people with advanced breast cancer that has continued to grow despite previous hormone treatments. The study will enroll about 510 adults whose cancer is ho…

This study is observing how well the drug trastuzumab deruxtecan works and its side effects for adults with advanced breast cancer in real-world settings. It will follow about 118 patients who are already planning to receive this treatment as part of their standard care. The main…

This early-stage study is testing a new experimental drug called BGB-43395, both alone and in combination with other cancer medications, for people with advanced hormone-positive breast cancer and other solid tumors. The main goals are to find safe dosage levels and see if the dr…

This study is testing whether a new two-drug combination called QL1706 can help control advanced breast cancer that has stopped responding to standard hormone treatments. Researchers will compare the new treatment against current standard care in 123 women whose cancer has return…

This study is testing a new combination of two cancer drugs, disitamab vedotin and tucatinib, for people with advanced or spreading breast or stomach cancer. The main goals are to find a safe and effective dose and to see if the combination can shrink tumors. It is for people who…

This study is testing whether the drug sacituzumab govitecan can help control metastatic breast cancer in people who have already received another targeted treatment called trastuzumab deruxtecan. The trial will enroll 75 adults with hormone receptor-positive, HER2-low breast can…

This is the first study in people to test a new drug called RLY-2608, which is designed to target a specific genetic mutation (PIK3CA) found in many advanced solid tumors and breast cancers. The main goals are to find the safest and most effective dose, check for side effects, an…

This study is testing whether adding the drug everolimus to a newer hormone therapy (elacestrant) works better for controlling advanced breast cancer than the hormone therapy alone. It is for people whose cancer has a specific mutation (ESR1) and has continued to grow despite sta…

This is a first-in-human study to test the safety and dosing of an experimental drug called BMS-986500. It will be given alone to people with various advanced solid tumors and in combination with other drugs to people with advanced breast cancer that has stopped responding to pri…

This study is for people with advanced breast cancer that has been stabilized after treatment. It compares a combination of two oral drugs, capecitabine and cyclophosphamide, against the doctor's usual choice of therapy to see which is better at keeping the cancer from growing ag…

This is the first-ever study in people of an experimental drug called metarrestin. The main goals are to find a safe dose and see if it can shrink tumors. It is for adults and teenagers (12+) with advanced solid tumors that have spread and have not been cured by standard treatmen…

This study is for people with a specific, harder-to-treat type of advanced breast cancer that is hormone-sensitive but has a non-luminal genetic pattern. It will compare a newer drug called trastuzumab deruxtecan against the current standard treatment (a CDK4/6 inhibitor plus hor…

This is the first human study testing a new experimental drug called BBO-10203 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find safe doses and see how the body processes the drug, both alone and when combined with oth…

This study is testing if adding the drug capivasertib to standard hormone therapy can help people with a specific type of advanced breast cancer stay on their treatment longer and maintain their quality of life. It is for adults whose cancer has continued to grow despite prior ho…

This early-stage study is testing a personalized treatment for advanced breast cancer. Doctors take a patient's own immune cells from a tumor sample, grow large numbers of them in a lab, and then infuse them back into the patient. The goal is to see if this 'TIL therapy' is safe …

This study is testing whether a new two-drug combination works better than current standard treatments for people with advanced breast cancer who have specific genetic mutations. It will involve about 500 adults whose cancer has spread and who have mutations in BRCA1, BRCA2, or P…

This study is testing a new drug called patritumab deruxtecan (U3-1402) for people with advanced breast cancer that is hormone-receptor positive and has stopped responding to standard hormone-blocking therapies and a specific type of targeted drug (CDK4/6 inhibitors). Participant…

This study tests whether matching drug combinations to a patient's specific tumor genetics can help control advanced breast cancer that has stopped responding to standard treatments. It will enroll 135 post-menopausal women whose cancer has progressed after initial therapy. Resea…

This study is testing a new treatment plan for people with advanced breast cancer that has stopped responding to standard hormone-based drugs. It will give 45 participants a newer targeted drug first, and then switch them to a different combination of pills. The main goal is to s…

This study is testing whether adding a biosimilar version of trastuzumab (a targeted therapy) to the chemotherapy drug eribulin works better than eribulin alone for people with advanced HER2-positive breast cancer. It's for patients whose cancer has continued to grow despite havi…

This study is testing a combination of two new drugs, MHB036C and MHB039A, for people with advanced breast cancer or other advanced solid tumors that have spread. The main goals are to see if the drug combination is safe, how the body processes it, and if it can shrink or control…

This is the first human study testing an experimental drug called MEN2312 for people with advanced breast cancer that has stopped responding to standard treatments. The trial aims to find the safest and most effective dose, testing the drug alone and in combination with other the…

This is the first study in people testing a new oral drug called BBI-940 for advanced or metastatic breast cancer. The main goal is to find a safe and tolerable dose, either alone or combined with another cancer drug. Researchers will enroll about 96 adults whose cancer has progr…

This study is testing whether the drug RC48-ADC can help control advanced breast cancer that has low levels of the HER2 protein. It's for patients who have already tried up to one chemotherapy treatment for their advanced cancer but haven't used this type of drug before. Research…

This global Phase 3 trial is testing which of two drug combinations works better to control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after standard hormone therapy. It will enroll about 540 adults whose cancer has returned or sp…

This early-stage study is testing a new experimental drug called ETX-636 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The trial will first check if the drug is safe and find the right dose, both when given alone and when combined wit…

This study is testing whether a smartphone app, combined with remote nurse support, helps people with cancer better manage the side effects of their chemotherapy. Over 400 adults with stomach, lung, breast, or colon cancer will use the app to track symptoms and get guidance. The …

This study is testing a new telehealth counseling program called ENGAGE, designed to help people with advanced cancer better manage their symptoms. It will compare ENGAGE to standard supportive care in 190 patients with Stage IV breast, prostate, lung, or colorectal cancer. The m…

This international study aims to find better ways to predict which patients with advanced breast, lung, bladder, or stomach cancer will benefit from a newer type of targeted cancer drug called antibody-drug conjugates (ADCs). Researchers will collect blood and tumor samples from …

This study aims to better understand the experience of patients with advanced breast cancer who are receiving care at home through hospice. Researchers will use regular telehealth check-ins to connect patients and their caregivers with their cancer care team. The goal is to learn…